» Articles » PMID: 28418023

Human Induced Pluripotent Stem Cells for Modelling Neurodevelopmental Disorders

Overview
Journal Nat Rev Neurol
Specialty Neurology
Date 2017 Apr 19
PMID 28418023
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

We currently have a poor understanding of the pathogenesis of neurodevelopmental disorders, owing to the fact that postmortem and imaging studies can only measure the postnatal status quo and offer little insight into the processes that give rise to the observed outcomes. Human induced pluripotent stem cells (hiPSCs) should, in principle, prove powerful for elucidating the pathways that give rise to neurodevelopmental disorders. hiPSCs are embryonic-stem-cell-like cells that can be derived from somatic cells. They retain the unique genetic signature of the individual from whom they were derived, and thus enable researchers to recapitulate that individual's idiosyncratic neural development in a dish. In the case of individuals with disease, we can re-enact the disease-altered trajectory of brain development and examine how and why phenotypic and molecular abnormalities arise in these diseased brains. Here, we review hiPSC biology and possible experimental designs when using hiPSCs to model disease. We then discuss existing hiPSC models of neurodevelopmental disorders. Our hope is that, as some studies have already shown, hiPSCs will illuminate the pathophysiology of developmental disorders of the CNS and lead to therapeutic options for the millions that are affected by these conditions.

Citing Articles

Engineering human cerebral organoids to explore mechanisms of arsenic-induced developmental neurotoxicity.

Wu X, Kreutz A, Dixon D, Tokar E Toxicol Appl Pharmacol. 2025; 496:117230.

PMID: 39842615 PMC: 11846691. DOI: 10.1016/j.taap.2025.117230.


Multifactorial approach is needed to unravel the maturation phases of human neurons derived from induced pluripotent stem cells.

Ben Mahmoud M, Ratkai A, Bauer K, Bencsik N, Szucs A, Schlett K Sci Rep. 2025; 15(1):2627.

PMID: 39837910 PMC: 11751176. DOI: 10.1038/s41598-024-81140-4.


A scalable, high-throughput neural development platform identifies shared impact of ASD genes on cell fate and differentiation.

Wang X, Lalli M, Thopte U, Buxbaum J bioRxiv. 2024; .

PMID: 39386704 PMC: 11463611. DOI: 10.1101/2024.09.25.614184.


Peering into the mind: unraveling schizophrenia's secrets using models.

Nani J, Muotri A, Hayashi M Mol Psychiatry. 2024; 30(2):659-678.

PMID: 39245692 DOI: 10.1038/s41380-024-02728-w.


Developmental neurotoxicity of PFOA exposure on hiPSC-derived cortical neurons.

Wu S, Xie J, Zhao H, Zhao X, Sanchez O, Rochet J Environ Int. 2024; 190:108914.

PMID: 39079332 PMC: 11406754. DOI: 10.1016/j.envint.2024.108914.


References
1.
Tang G, Gudsnuk K, Kuo S, Cotrina M, Rosoklija G, Sosunov A . Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014; 83(5):1131-43. PMC: 4159743. DOI: 10.1016/j.neuron.2014.07.040. View

2.
Patriarchi T, Amabile S, Frullanti E, Landucci E, Lo Rizzo C, Ariani F . Imbalance of excitatory/inhibitory synaptic protein expression in iPSC-derived neurons from FOXG1(+/-) patients and in foxg1(+/-) mice. Eur J Hum Genet. 2015; 24(6):871-80. PMC: 4820038. DOI: 10.1038/ejhg.2015.216. View

3.
Dragunow M . The adult human brain in preclinical drug development. Nat Rev Drug Discov. 2008; 7(8):659-66. DOI: 10.1038/nrd2617. View

4.
Glessner J, Wang K, Cai G, Korvatska O, Kim C, Wood S . Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009; 459(7246):569-73. PMC: 2925224. DOI: 10.1038/nature07953. View

5.
Cheng L, Hansen N, Zhao L, Du Y, Zou C, Donovan F . Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell. 2012; 10(3):337-44. PMC: 3298448. DOI: 10.1016/j.stem.2012.01.005. View